Chemistry:Imgatuzumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from rat) |
| Target | EGFR |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6434H9942N1718O2016S44 |
| Molar mass | 145028.96 g·mol−1 |
Imgatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It is an anti-EGFR antibody[1] that acts as an immunomodulator.[2][3]
The drug was developed by Genentech/Roche.
References
- ↑ "ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells". Oncotarget 8 (28): 45432–45446. July 2017. doi:10.18632/oncotarget.17139. PMID 28467975.
- ↑ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107". WHO Drug Information 26 (2). https://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Imgatuzumab, American Medical Association.
